Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOR103 in Multiple Sclerosis
NCT01517282Phase 2Completed
- Sponsor
- MorphoSys AG
- Start
- Jan 2012
- Primary completion
- Jan 2014
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of namilumab in multiple sclerosis (MS), sponsored by MorphoSys AG. Started Jan 2012; status: completed.
02
Drugs
namilumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01517282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01517282.